Type to search


National Institutes of Health (NIH) is Expected to Share Precision Medicine Study Data with the Participants Very Soon


National Institutes of Health is going to share the results of genetic testing and analysis to the nearly 200,000 Americans. Who trusted and shared their medical records of DNA and detailed behavioral surveys to the federal scientists. Till date, none of the study conducted by any government organization has declared the genetic data to the contributor or the individual. The data given to the participant will provide a deep drive look about genetic traits. As well as other factors related to genetic which may influence the efficiency of prescription drugs. National Institutes of Health is going to offer counseling services based on genetics to all research study participants.

National Institutes of Health will be offering genetic statistics and data and counseling services. These are free of charge to the 25000 enrolled participants in the pilot program. After agreeing to the DNA analysis. Agency also said that till date approximately 51% percent of participants are from historically marginalized ethnic and racial backgrounds. The program has launched before two years and fully enrolled by approximately 188,000 people. In this program almost a quarter-million people filled initial agreement forms. At this big scale no other study is available in which big diversified data is genotyped or sequenced.

The National Institutes of Health is planning to catalog around one million participant’s health and DNA data. This projects goal is to allow scientist and researchers to access open source. And anonymized data which will reveal previously unknown genetic information and population trends. This study also expected to embrace the potential to restructure medical practices. And overall healthcare and pharmaceutical industry. In 2016, the US Congress authorized a budget of US$ 1.5 billion for the study. Which aims to improve the understanding of the medical community about the health of the population and make healthcare services more specific to individuals. The National Institutes of Health has mentioned the potential of using genetics.  This is in order to decide most effective pharmaceutical treatments in the emerging field of pharmacogenomics.

Robert Ray

I am an Robert, independent researcher as well as speaker exploring about hybrids and electric vehicles, information technology trends, and markets. I'm also covering topics such as cloud computing, digital transformation, enterprise mobility, and big data analytics too. I worked on Google's car team in its early years and am an advisor and/or investor for car OEMs and many of the top startups in robocars, delivery robots, sensors, and even some flying cars.